Leidos will match high-scoring, unfunded National Institutes of Health (NIH) proposals with private biomedical foundations and/or industries seeking to fund promising research. Foundations will have access to peer-reviewed research proposals that directly relate to their funding priorities, industry will have access to a rich pipeline of early stage and translational research proposals that align with its priorities, while applicants with strong research proposals will be provided with a second opportunity to secure funding. The foundations, industries, applicants, and NIH all will benefit from this synergy.

EPA's Office of Pollution Prevention and Toxics, Chemistry, Economic and Sustainable Strategies Division oversees the Pollution Prevention (P2) Grant Program to support State and Tribal P2 Programs administer P2 projects that will help businesses identify better environmental strategies and solutions for reducing or eliminating waste at the source. EPA anticipates it will award approximately $7.94 million in federal P2 grant funding ($3.97 million in FY 2016 and $3.97 million in FY 2017) to support two-year grant agreements. Grants will be awarded and managed by EPA's ten Regional P2 Program Offices. P2 grants are dependent on Congressional appropriation and the quality of proposals received.

With this Dear Colleague Letter, NSF is providing advance notice of a change in the eligibility of prospective applicants to the Graduate Research Fellowship Program (GRFP) to allow the community to plan accordingly. Effective as of the 2017 competition (Fall 2016 deadlines), NSF will limit graduate students to only one application to the GRFP, submitted either in the first year or in the second year of graduate school. No change is made to the eligibility of undergraduates, of bachelor's degree holders without any graduate study, or of individuals who have had an interruption in graduate study of at least two consecutive years.

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Cell-based therapies, especially immune cells, have the potential to revolutionize human healthcare in various different contexts, including cancer and personalized medicine. For example, CAR (Chimeric antigen receptor) T-cell therapy for cancer requires modification, in vitro culture and expansion of human T-cells.   Manufacturing of therapeutic cells as the end product presents major engineering challenges.  New therapies and cell-based products depend critically on the development of robust, reliable and reproducible biomanufacturing technologies.

This program will investigate the base of the Selawik River basin aquatic food web, and link it to the anticipated increase in terrestrial inputs of carbon and nitrogen to the aquatic ecosystem as a result of climate change. The main objectives are: 1) assess the quality and quantity of terrestrial dissolved organic carbon (DOC), organic and inorganic nitrogen, and phosphorus released with increased soil thaw depth during spring and early summer, and its entry to the aquatic ecosystem; 2) quantify change in aquatic microbial, mainly bacterial, respiration and production rates with change in DOC quality and quantity; and 3) examine how change in terrestrial DOC and nitrogen inputs to the aquatic ecosystem might alter the rate of phytoplankton primary production, the community composition, and energy (lipid) content.

The National Science Foundation (NSF) seeks to develop and nurture a national innovation ecosystem that builds upon research to guide the output of scientific discoveries closer to the development of technologies, products and processes that benefit society.

The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinsons Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

The purpose of this funding opportunity announcement (FOA) is to 1) expand the collection of clinical data and biological specimens in the NINDS Parkinsons Disease Biomarkers Program (PDBP), a community research resource, to include data from patients with Lewy Body Dementias (including Dementia with Lewy Bodies and Parkinson's Disease with Dementia), and 2) to support hypothesis-driven clinical research to discover biomarkers that will improve the efficiency and outcome of Phase II clinical trials for the Lewy Body dementias and to provide an expansion of this existing research resource center for dissemination of information and access by the scientific community for further advancing research in this field. Applications may include both of these goals if justified.

NIST is soliciting applications for financial assistance for Fiscal Year 2016 (FY16) within the following NIST Laboratory grant programs: (1) the Material Measurement Laboratory (MML) Grant Program; (2) the Physical Measurement Laboratory (PML) Grant Program; (3) the Engineering Laboratory (EL) Grant Program; (4) the Fire Research (FR) Grant Program; (5) the Information Technology Laboratory (ITL) Grant Program; (6) the Communications Technology Laboratory (CTL) Grant Program; (7) the NIST Center for Neutron Research (NCNR) Grant Program; (8) the Center for Nanoscale Science and Technology (CNST) Grant Program; (9) the Special Programs Office (SPO) Grant Program; (10) the Standards Coordination Office (SCO) Grant Program; (11) the International and Academic Affairs Office (IAAO) Grant Program; and (12) the Associate Director for Laboratory Programs (ADLP) Grant Program.

NIST is soliciting applications for financial assistance for Fiscal Year 2016 (FY16) within the following NIST Laboratory grant programs: (1) the Material Measurement Laboratory (MML) Grant Program; (2) the Physical Measurement Laboratory (PML) Grant Program; (3) the Engineering Laboratory (EL) Grant Program; (4) the Fire Research (FR) Grant Program; (5) the Information Technology Laboratory (ITL) Grant Program; (6) the Communications Technology Laboratory (CTL) Grant Program; (7) the NIST Center for Neutron Research (NCNR) Grant Program; (8) the Center for Nanoscale Science and Technology (CNST) Grant Program; (9) the Special Programs Office (SPO) Grant Program; (10) the Standards Coordination Office (SCO) Grant Program; (11) the International and Academic Affairs Office (IAAO) Grant Program; and (12) the Associate Director for Laboratory Programs (ADLP) Grant Program.

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The intention of this Funding Opportunity Announcement is to improve the prevention, diagnosis, and treatment of vulvodynia.  By definition, vulvar discomfort or pain without a clear etiology is termed vulvodynia. Some organizations use the term vulvodynia to indicate vulvar pain of unknown etiology for more than 3 months.  For the purposes of this announcement, vulvodynia and vulvar pain will be used interchangeably.  The overall incidence of vulvodynia has been reported as 4.2 cases per 100 person-years in one population based study, with others estimating that persistent vulvar pain affects 9 to 18 percent of women at some point during their lifetime. Current evidence suggests that incidence rates vary by age, ethnicity and marital status.

This Research Announcement (RA) solicits ground-breaking single-investigator proposals from junior faculty for research and development in the areas of physical sciences, engineering, materials, mathematics, biology, computing, informatics, and manufacturing of interest to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO) and Microsystems Technology Office (MTO).

This Research Announcement (RA) solicits ground-breaking single-investigator proposals from junior faculty for research and development in the areas of physical sciences, engineering, materials, mathematics, biology, computing, informatics, and manufacturing of interest to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO) and Microsystems Technology Office (MTO).

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

The Chemical Security Program (CSP) partners with government, security, academic, and industrial communities in Africa, the Middle East, and Asia, to strengthen their ability to thwart chemical attacks. CSP accomplishes this aim by sponsoring projects designed to identify and address chemical security vulnerabilities and identify and investigate early warning signs of chemical attacks in preparation.

The Chemical Security Program (CSP) partners with government, security, academic, and industrial communities in Africa, the Middle East, and Asia, to strengthen their ability to thwart chemical attacks. CSP accomplishes this aim by sponsoring projects designed to identify and address chemical security vulnerabilities and identify and investigate early warning signs of chemical attacks in preparation.

I-Corps@Ohio is a statewide program to assist faculty and graduate students from Ohio universities and colleges to validate the market potential of their technologies and assist with launching startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps program, which has proven to increase innovation, entrepreneurship, and industry collaboration. I-Corps@Ohio is an initiative of the Ohio Department of Higher Education.

Together with University Advancement, the Office for the Advancement of Research & Scholarship (OARS) is rolling out an new crowdfunding platform called HawksNest. Through HawksNest, alumni, family, and friends of the university can directly support the research, scholarship, and service projects of Miami University students, faculty, and staff. This is how HawksNest works: * Any Miami University student, faculty, or staff member may complete an online application to have a project considered for funding. * An internal review team assesses applications and posts approved projects on HawksNest for a maximum of 45 days. * Potential donors visit the site to learn about and pledge funds to approved projects. * Once a funding goal has been met, the project can begin! * Project managers use the site to keep donors up-to-date with information on the project's progress.